Risk-Adapted Omission of Level Va Irradiation in Nasopharyngeal Carcinoma
Trial statusNot yet recruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-70
SponsorFujian Cancer Hospital
About this trial
This is a randomized, phase III, prospective, multi-center trial in newly diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis. This study will evaluate whether omitting Level Va irradiation in patients without these risk features does not compromise regional control or survival, with the goal of providing robust evidence to guide further personalization of NPC radiotherapy.
Eligibility criteria
Qualifiers
Pathologic diagnosis (pathologically confirmed by nasopharyngeal biopsy) was nasopharyngeal carcinoma;
No distant metastatic;
Eastern Cooperative Oncology Group (ECOG) score of 0 or 1;
Signing informed consent;
Disqualifiers
Ipsilateral Level IIb involvement;
Ipsilateral Level III nodes involvement;
Ipsilateral positive lymph nodes below the cricoid cartilage (Level IV or Vb-c);
Disease progression during IMRT;
Trial design
Treatments tested in this trial
- Omission of Level Va Irradiation in Nasopharyngeal Carcinoma
Treatment groups
474 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov